- Home
- LXRX vs SIBN Comparison
LXRX vs SIBN Comparison
Compare LXRX & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | SIBN |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.9M | 576.4M |
| IPO Year | 2000 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LXRX | SIBN |
|---|---|---|
| Price | $1.69 | $12.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $4.15 | ★ $24.13 |
| AVG Volume (30 Days) | ★ 2.6M | 491.9K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | 41.33 |
| EPS | ★ N/A | N/A |
| Revenue | $49,803,000.00 | ★ $67,301,000.00 |
| Revenue This Year | N/A | $16.95 |
| Revenue Next Year | N/A | $14.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 60.24 | 21.53 |
| 52 Week Low | $0.36 | $12.15 |
| 52 Week High | $1.83 | $21.89 |
Technical Indicators
Market Signals| Indicator | LXRX | SIBN |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 41.18 |
| Support Level | $1.08 | N/A |
| Resistance Level | $1.81 | $13.49 |
| Average True Range (ATR) | 0.11 | 0.58 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 65.00 | 38.76 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.